ImmunoCellular Therapeutics, Ltd. 4
4 · ImmunoCellular Therapeutics, Ltd. · Filed Oct 22, 2013
Insider Transaction Report
Form 4
Yu John S
DirectorSecretary
Transactions
- Sale
Common Stock
2013-10-18$2.91/sh−231,381$673,226→ 0 total(indirect: By Trust) - Gift
Common Stock
2013-10-21−36,006→ 10,000 total - Exercise/Conversion
Stock Option (right to buy)
2013-10-18−231,381→ 68,619 totalExercise: $0.25Exp: 2014-02-25→ Common Stock (231,381 underlying) - Exercise/Conversion
Common Stock
2013-10-18$0.25/sh+231,381$57,845→ 241,381 total - Gift
Common Stock
2013-10-18+231,381→ 231,381 total(indirect: By Trust) - Exercise/Conversion
Common Stock
2013-10-21$0.25/sh+36,006$9,002→ 46,006 total - Gift
Common Stock
2013-10-21+36,006→ 36,006 total(indirect: By Trust) - Exercise/Conversion
Stock Option (right to buy)
2013-10-21−36,006→ 32,613 totalExercise: $0.25Exp: 2014-02-25→ Common Stock (36,006 underlying) - Gift
Common Stock
2013-10-18−231,381→ 10,000 total - Sale
Common Stock
2013-10-21$2.92/sh−36,006$105,080→ 0 total(indirect: By Trust)
Footnotes (5)
- [F1]These shares are being transferred to the reporting person's Family Trust.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported is an average price. The prices ranged from $2.9000 to $2.9500 per share. Full information regarding the number of shares sold at each separate price within the range set forth in this footnote is available upon request by the SEC, the issuer or a security holder of the issuer.
- [F4]The price reported is an average price. The prices ranged from $2.9000 to $2.9800 per share. Full information regarding the number of shares sold at each separate price within the range set forth in this footnote is available upon request by the SEC, the issuer or a security holder of the issuer.
- [F5]Fully vested.